Outcome of radiotherapy for pituitary adenomas

详细信息    查看全文

• 作者：Patricia Sebastian^a ; ^{drpat@cmcvellore.ac.in" class="auth_mail" title="E-mail the corresponding author} ; Rajesh Balakrishnan^a ; ^{rajeshb@cmcvellore.ac.in" class="auth_mail" title="E-mail the corresponding author} ; Bijesh Yadav^b ; ^{yadavbijesh@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Subhashini John^a ; ^{subha@cmcvellore.ac.in" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Radiotherapy ; Pituitary ; Complications ; Visual ; Hypopituitarism
• 刊名：Reports of Practical Oncology & Radiotherapy
• 出版年：2016
• 出版时间：September-October 2016
• 年：2016
• 卷：21
• 期：5
• 页码：466-472
• 全文大小：512 K

文摘

The aim of this study was to analyze the outcome and toxicities and its correlation to patient related and treatment related factors.

Background

Pituitary adenomas are treated by radiation therapy (RT) as one of the modalities along with surgery and medical therapy. RT to pituitary adenomas is a challenge due to adjacent dose limiting structures such as optic apparatus and hypothalamus.

Materials and methods

Between January 2004 and December 2010, 94 patients treated for pituitary adenoma with RT who had hospital records of a minimum follow-up of 1 year were included in the analysis. Tests of correlation were done with regards to treatment factors.

Results

Male preponderance was noted in our patient population. Nonfunctioning and functioning tumors were equal in number in this series. Hypopituitarism was associated in 58.5% of patients prior to RT. Radiological tumor progression was seen in one patient (1/94) who had a nonfunctioning tumor. Among functioning tumors, biochemical remission was seen in 93.6% of patients at a median follow-up of 6 years.

Conclusions

Visual complication was seen in 5.3% of patients and worsening or new onset hypopituitarism was seen in 6.4%. Conventional 3-field technique was associated with significantly more visual complication compared to Stereotactic Radiation Therapy (SRT) technique. Doses ≤50.4 Gy showed a trend of reduced rate of visual and endocrine complications with no compromise in efficacy.